Questions?1-833-393-4363
†In clinical trials of 665 people on VABYSMO and 664 people on aflibercept 2 mg, people gained an average of 5 letters on an eye chart at 1 month for both treatments. On average, people gained and maintained 6 letters over 1 year with VABYSMO, similar to aflibercept 2 mg.
‡After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response during your first year of treatment. Dosing may vary.
§VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.
With VABYSMO, I’m not having to run back and forth for my injections as much as I was. We have more time to do things now with the family.
Patient experiences may vary.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.